Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-11-24
2002-04-30
Rose, Shep K. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
06380173
ABSTRACT:
The present invention relates to the use of low-molecular-weight heparins for the prevention and treatment of trauma of the central nervous system and in particular of spinal, cranial or craniospinal trauma.
The invention also relates to the use of low-molecular-weight heparins for the preparation of a medicament for the prevention and treatment of trauma of the central nervous system and in particular of spinal, cranial or craniospinal trauma.
Standard heparin is a sulphated polysaccharide having an average molecular weight of 12,000-15,000 daltons which is isolated from bovine, ovine and porcine intestinal mucous membranes. Heparin is clinically used for the prevention and treatment of thromboembolic disorders but sometimes causes haemorrhages.
Over the past ten years, heparin has been gradually replaced by low-molecular-weight heparins which no longer exhibit or which exhibit to a lesser degree the disadvantage of causing bleeding and which now require only one injection per day instead of 2 to 3 injections per day for standard heparin. These low-molecular-weight heparins are prepared in particular by fractionation, controlled depolymerization of heparin or by chemical synthesis. They have an anti-Xa activity/anti-IIa activity ratio greater than 2.
It has now been found that low-molecular-weight heparins reduce the size of the trauma of the central nervous system and in particular of spinal, cranial or craniospinal trauma.
Traumas of the central nervous system (SNC trauma or neurotrauma) relate to trauma of the brain (cerebral trauma) and traumas of the spinal cord (medullary trauma). They are the consequence of a shock at the level of the central nervous system (car, motorbike, skiing or swimming-pool accident and the like) which is often but not always accompanied by fractures. The consequences of these traumas are neurological disorders such as epilepsy, impairment of consciousness, motor problems, amnesia, aggressiveness and psychoaffective deficiency.
REFERENCES:
patent: 5605891 (1997-02-01), Prino et al.
patent: 0 101 141 (1994-02-01), None
patent: 0 582 330 (1994-02-01), None
patent: 0 287 477 (1998-10-01), None
patent: WO 92 11294 (1992-07-01), None
Gorio et al., Glycosaminoglycans in nerve injury: Ii. Effects on transganglionic degeneration and on the expression of neurotrophic factors., J. Neuroscience Research 1996, 46/S, 572-580.
Eckenstein et al., Acidic and basic fibroblast growth factors in the nervous system: Distribution and differential alteration of levels after injury of central versus peripheral nerve, J. Neuroscience. 1991, 11/2, 412-419.
Green et al., Prevention of thromboembolism after spinal cord injury using low molecular weight heparin., Annals of Internal Medicine. 113(8):571-574 (Oct. 15, 1990.
Kay et al., Low molecular weight heparin for the treatment of acute ischemic stroke., New England J. of Med. 1995, 333/8 1588-1593.
Stutzmann Jean-Marie
Uzan Andre
Wahl Florence
Aventis Pharma S.A.
Jagoe Donna
Newman Irving
Rose Shep K.
LandOfFree
Use of low-molecular-weight heparins for the prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of low-molecular-weight heparins for the prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of low-molecular-weight heparins for the prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2908371